ClinicalTrials.gg

Urinary Tract Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 806 studies for Urinary Tract Infections across more than 10 countries. 134 are recruiting or about to start. 550 of them are mainly about Urinary Tract Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Bacteriuria: 852 studies, 138 open.

ClinicalTrials.gov finds 1,002 studies for Urinary Tract Infections. How that becomes 803 here

This page counts the studies the registry files under Urinary Tract Infections, and those it files under no condition that list Urinary Tract Infectionsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,002Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −39Filed under a narrower condition, counted on its own pageSchistosomiasis haematobia 21 · Bacteriuria 18
  3. −48List Urinary Tract Infections as a condition, but the registry did not file them under itMost often written as “Complicated Urinary Tract Infection” (8), “Urinary Tract Infection Bacterial” (6), and “Complicated Urinary Tract Infection (cUTI)” (4). The registry filed them under other conditions only, most often Sepsis (8) and Pyelonephritis (4).
  4. −112Match it another way41 name it in the title, 8 in a keyword, and 63 by a synonym or other text the search reads.
  5. 803The count on this page83 of them list Urinary Tract Infections in their own words; the registry filed them under no condition.

Status

Completed
443
Status unknown
99
Recruiting
84
Terminated
56
Not yet recruiting
41
Withdrawn
39

Phase

Phase 4
110
Phase 3
91
Phase 2
89
Phase 1
42
Early Phase 1
14

Where

United States
273
France
58
Canada
48
Spain
32
Italy
32
United Kingdom
31

Who develops what

Add Urinary Tract Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 6 companies, 6 with this as their studies’ main aim; 1 with a live phase 3 study; 3 primary completions in the next 12 months. Compare GlaxoSmithKline, Wockhardt and Joincare Pharmaceutical Group Industry here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ImipenemRecent, repeated
Evidence
  • NCT06569056 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Imipenem and Cilastatin Sodium” · registered Aug 2024
  • NCT06144060 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Imipenem and Cilastatin Sodium” · registered Nov 2023
  • NCT05887908 · Meiji Seika Pharma Co., Ltd. · Phase 3 · comparator · “imipenem/cilastatin” · registered Apr 2023
  • NCT02321800 · Shionogi · Phase 2 · comparator · “Imipenem/cilastatin” · registered Nov 2014
  • NCT00690378 · Pfizer · Phase 2 · comparator · “Imipenem/Cilastatin” · registered May 2008
Merck & Co., Inc67% of its industry studies23 studies
CilastatinRecent, repeated
Evidence
  • NCT06569056 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Imipenem and Cilastatin Sodium” · registered Aug 2024
  • NCT06144060 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Imipenem and Cilastatin Sodium” · registered Nov 2023
  • NCT05887908 · Meiji Seika Pharma Co., Ltd. · Phase 3 · comparator · “imipenem/cilastatin” · registered Apr 2023
  • NCT02321800 · Shionogi · Phase 2 · comparator · “Imipenem/cilastatin” · registered Nov 2014
  • NCT00690378 · Pfizer · Phase 2 · comparator · “Imipenem/Cilastatin” · registered May 2008
Merck & Co., Inc50% of its industry studies23 studies
NitrofurantoinRecent, repeated
Evidence
  • NCT07871968 · Alembic Therapeutics · Phase 2 · live · comparator · “Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule)” · registered Oct 2026
  • NCT05630833 · GlaxoSmithKline · Phase 3 · comparator · “Nitrofurantoin” · registered Nov 2022
  • NCT04187144 · GlaxoSmithKline · Phase 3 · comparator · “Nitrofurantoin” · registered Dec 2019
  • NCT04020341 · GlaxoSmithKline · Phase 3 · comparator · “Nitrofurantoin” · registered Jul 2019
Teva Pharmaceutical Industries, Ltd.50% of its industry studiesUS: off-patent, 27 generics marketed22 studies

15 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
U101☆ Track1 live phase-3 study: NCT07184827TCM Biotech International Corp.

The 1 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 May 2027 est.Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine HTD formulation 2 · GlaxoSmithKline · Phase 2 main aimNCT06702449 A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age — primary endpoint: Part 1 and 2: Number of participants reporting solicited administration site adverse events (AEs) · 448 enrolled
  • 1 Sept 2027 est.Ertapenem-zidebactam, Ertapenam-Zidebactam · Wockhardt · Phase 2 named, not the main aimvs avibactam, ceftazidime drug combinationNCT07840105 This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis — primary endpoint: Clinical Outcome at Test of Cure (TOC) - mMITT Analysis Set: · 279 enrolled
  • 30 Oct 2027 est.Amdinocillin Pivoxil · Alembic Therapeutics · Phase 2 main aimvs NitrofurantoinNCT07871968 A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection — primary endpoint: Incidence of Treatment Emergent Adverse Events · 100 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Urinary Tract Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 1 open · Beta-lactamase inhibitors 6 · NSAIDs 3

Coming up

49studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 24 (29%) stop at 75 or younger. 16 (19%) take children under 18. 27 (32%) are for women only and 1 (1%) for men only; 16 (19%) take healthy volunteers.

Recruiting studies that take each age, of 84
AgeWomenMen
108 (10%)8 (10%)
1865 (77%)43 (51%)
3066 (79%)42 (50%)
4067 (80%)43 (51%)
5065 (77%)42 (50%)
6567 (80%)45 (54%)
7565 (77%)44 (52%)
8558 (69%)41 (49%)

Across all 806 studies, recruiting or not: 31% stop at 75 or younger and 24% at 65; 23% take children; 32% are for women only and 3% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urinary Tract Infections studies take

Of 50 phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo8–34 · 16 studies——
Phase 229 mo16–38 · 30 studies——
Phase 320 mo14–32 · 37 studies17 mo12–28 · 23 studies—
Phase 437 mo22–46 · 50 studies—39 mo22–50 · 44 studies
Interventional, no phase22 mo8–37 · 153 studies—23 mo8–39 · 136 studies
Observational26 mo11–53 · 84 studies—43 mo12–59 · 72 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 806. Browse all 806 → or search them.